• FluoGuide posted a net loss of DKK 12.82 million in Q2 2026, widening from DKK 8.95 million a year earlier.
• Operating loss widened to DKK 14.92 million from DKK 9.85 million, while other operating income rose to DKK 92,000 from DKK 57,000.
• Cash, cash equivalents and securities fell to DKK 49.82 million at June 30 from DKK 78.8 million at end-2025.
• FG001 progress included FDA authorization to start CT-006 under a U.S. IND, with the first U.S. site activated.
• Phase 2 oral head and neck cancer trial reported positive Part 1 results, meeting its primary endpoint and selecting 0.30 mg/kg as optimal dose.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fluoguide A/S published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.